Medications

Axicabtagene ciloleucel slows large B-cell lymphoma

(HealthDay)—For patients with refractory or relapsed large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) leads to improvements in event-free survival and response compared with standard care, according to a study published ...

Medications

New hope for patients with relapsed large B-cell lymphoma

Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, ...

Oncology & Cancer

Thanks to clinical trials, big leaps made in lymphoma treatment

Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...

Oncology & Cancer

Receptor structure reveals new targets for cancer treatment

A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule—its role in the ...

Oncology & Cancer

Fundamental feature of aggressive lymphomas discovered

Research led by the University of Southampton has revealed a new fundamental feature of aggressive B-cell lymphomas which could open the door to further research into early detection and treatment of the disease.

page 3 from 13